Results 61 to 70 of about 27,075 (224)

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy

Cell Death and Disease
Olaparib has been approved as a therapeutic option for metastatic pancreatic ductal adenocarcinoma patients with BRCA1/2 mutations. However, a significant majority of pancreatic cancer patients have inherent resistance or develop tolerance to olaparib ...
Mingming Xiao, Jing Yang, Mingwei Dong, Xiaoqi Mao, Haoqi Pan, Yalan Lei, Xuhui Tong, Xiaoning Yu, Xianjun Yu, Si Shi   +9 more
doaj   +1 more source

ZUP1 promotes DNA repair and immune evasion to drive olaparib resistance in triple-negative breast cancer

Journal of Advanced Research
Introduction: Olaparib resistance limits its therapeutic efficacy in triple-negative breast cancer (TNBC). Exploring the mechanisms underlying olaparib resistance and developing combination strategies are of great clinical significance for improving the ...
Shanshan Huang, Yu Qiu, Linyu Wu, Yi Xie, Zhiting He, Yingqing Li, Xinhua Xie   +6 more
doaj   +1 more source

PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF-кB pathway activity and DNA damage response induced by Idarubicin

Acta Biochimica et Biophysica Sinica, 2021
Idarubicin (IDA), an anthracycline antineoplastic drug, is commonly used in the treatment of acute myeloid leukemia (AML) with reasonable response rates and clinical benefits.
Ke Bo, Li Anna, Fu Huan, Kong Chunfang, Liu Tingting, Zhu Qingqing, Zhang Yue, Zhang Zixia, Chen Chen, Jin Chenghao   +9 more
doaj   +1 more source

Combinations of ATR, Chk1 and Wee1 inhibitors with Olaparib are active in Olaparib resistant Brca1 proficient and deficient murine ovarian cells

, 2022
Simple Summary Poly(ADP-ribose) polymerases inhibitors (PARPis), including olaparib, have been recently approved for ovarian carcinoma treatment and PARPi resistance has already been observed in the clinics.
Chiappa, Michela, Damia, Giovanna, Lupi, Monica, Anselmi, Martina, Guffanti, Federica, Panini, Nicolò, Wiesmüller, Lisa   +6 more
core   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis

European Urology Open Science
Background and objective: Olaparib is one of the earliest approved treatment options for metastatic castration-resistant prostate cancer (mCRPC). This systematic review and network meta-analysis aimed to determine the optimal olaparib strategy for ...
Yixian Li, Zongyu Li, Hongxia Lu, Pengjie Shi, Yiting Liu, Lilong Liu, Ke Chen   +6 more
doaj   +1 more source

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation

Cancer Medicine, 2018
Cholangiocarcinoma (CCA) is a highly malignant tumor with resistance to radiotherapy alone. Olaparib, a highly potent poly(ADP‐ribose) polymerase (PARP) inhibitor, has been shown to sensitize many types of tumor to radiotherapy.
Yize Mao, Xin Huang, Zeyu Shuang, Guohe Lin, Jun Wang, Fangting Duan, Jianlin Chen, Shengping Li   +7 more
doaj   +1 more source

Olaparib za zdravljenje raka jajčnikov [PDF]

, 2019
Olaparib vam je zdravnik predpisal, ker gre pri vas za ponovitev bolezni in imate ugotovljeno mutacijo v genih BRCA 1 ali BRCA 2 (izraz BRCA je kratica, ki v slovenskem prevodu pomeni „gen dovzetnosti za pojav raka dojk“).
Škof, Erik
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source